Premium
Some clinical and radiographical features of submerged and non‐submerged titanium implants. A 5‐year follow‐up study.
Author(s) -
Schenk Günther,
Flemmig Thomas Frank,
Betz Thomas,
Reuther Jürgen,
Klaiber Bernd
Publication year - 1997
Publication title -
clinical oral implants research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.407
H-Index - 161
eISSN - 1600-0501
pISSN - 0905-7161
DOI - 10.1034/j.1600-0501.1997.080510.x
Subject(s) - mucositis , medicine , bleeding on probing , dentistry , tetracycline , implant , peri implantitis , randomized controlled trial , clinical trial , scaling and root planing , surgery , chronic periodontitis , periodontitis , antibiotics , radiation therapy , microbiology and biotechnology , biology
The purpose of this controlled case series was to assess the adjunctive efficacy of controlled topical tetracycline HCl application in the treatment of infection associated periimplant mucositis or mucosal hyperplasia. Eight patients with at least 2 endosseous implants showing clinical signs of peri‐implant mucosal hyperplasia or mucositis were enrolled. All implants received supra‐ and subgingival scaling, with half of the implants receiving adjunctive controlled local delivery of tetracycline HCI (test). Control implants did not receive any other therapy aside from scaling. Clinical parameters were assessed at baseline, 4. and 12 weeks. Scaling plus controlled local delivery of tetracycline HCl markedly reduced peri‐implant mucosal hyperplasia in 4 of 5 test implants and demonstrated a trend towards a reduction of bleeding on probing scores. Scaling alone had no effect on mucosal hyperplasia in the 2 control implants presenting with this condition nor bleeding on probing scores. In both groups, plaque index scores were slightly reduced at 4 weeks but returned to baseline values at 12 weeks, whereas pocket probing depths, clinical attachment levels. and probing bone levels remained unchanged during the course of the trial. The observed trends suggest that scaling plus controlled local delivery of tetracycline HCI may have beneficial effects. Randomized controlled trials employing a sample size high enough to reach sufficient statistical power are needed to definitively assess the efficacy of controlled local tetracycline HCl delivery on peri‐impiant diseases.